The U.S. Food and Drug Administration has approved the prescription-free sale of the second opioid overdose reversal drug, its manufacturer Harm Reduction Therapeutics said on Friday.
The approval of the drug, called RiVive, will provide patients with another over-the-counter option in the United States, where drug-related overdose deaths surpassed 100,000 in 2021.
Harm Reduction said it anticipates that RiVive will be available early next year, primarily to harm-reduction organizations and state governments. The not-for-profit drugmaker said it would make at least 200,000 doses available for free. RiVive is a nasal spray version of naloxone, which rapidly reverses or blocks the effects of opioids, restoring normal respiration, especially when given within minutes of the first signs of an overdose.
"If we are able to have partners step forward and help fund our work, we can further lower the cost of RiVive, or increase the amount that we give away for free," the company's co-founder and CEO Michael Hufford said.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Second Harvest to launch ‘Food As Medicine’ initiative to screen people for food insecurityA $425,000 grant will help screen up to 1,000 people in Santa Clara and San Mateo counties in the next three years.
Read more »
Wegovy weight-loss injection factory plagued by sterile-safety failuresThe factory that fills the self-injection pens for booming weight-loss drug Wegovy has repeatedly breached U.S. sterile-safety rules in recent years and staff have failed to perform required quality checks, a Reuters review of regulatory documents shows. The breaches at Catalent, the Wegovy pen filler, were found by inspectors from the U.S. Food and Drug Administration who visited the plant in Brussels in October 2021 and August 2022 to check on its compliance with manufacturing regulations, according to detailed FDA reports on the inspections, obtained by Reuters under freedom of information laws. There is no evidence that Catalent's compliance failures resulted in harm to users of Wegovy.
Read more »
DeSantis says he would appoint RFK Jr. to the FDA or CDCFlorida governor and 2024 presidential hopeful Ron DeSantis (R) said Wednesday that, although he would not choose Robert F. Kennedy Jr. as a running mate, he would consider appointing him to lead the Food and Drug Administration or the Centers for Disease Control and Prevention.
Read more »
Postpartum depression pill on the fast track for FDA approvalFor Sahar McMahon, having her second baby was a completely different experience than having her first. Her postpartum negative mood, low energy and inability to focus were feelings that she had never felt before.
Read more »
DeSantis: I’d Appoint Anti-Vaxxer RFK Jr. to Lead CDC or FDAGOP presidential candidate Ron DeSantis boasted on Wednesday that as president he’d “sic” anti-vaccine conspiracist Robert F. Kennedy Jr. on the CDC or FDA by appointing him to lead the public health organizations.
Read more »